Development of High Drug-loading Nanomicelles Targeting Steroids to the Brain

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2014 Jan 1

PMID 24379663

Citations 9

Authors

Sijia Zheng

Yanqi Xie

Yuan Li

Ling Li

Ning Tian

Wenbo Zhu

GuangMei Yan

Chuanbin Wu

Haiyan Hu

Affiliations

Soon will be listed here.

Abstract

The objective of this research was to develop and evaluate high drug-loading ligand-modified nanomicelles to deliver a steroidal compound to the brain. YC1 (5α-cholestane-24-methylene-3β, 5α, 6β, 19-tetraol), with poor solubility and limited access to the brain, for the first time, has been proved to be an effective neuroprotective steroid by our previous studies. Based on the principle of 'like dissolves like', cholesterol, which shares the same steroidal parent nucleus with YC1, was selected to react with sodium alginate, producing amphiphilic sodium alginate- cholesterol derivatives (SACDs). To increase the grafting ratio and drug loading, cholesterol was converted to cholesteryl chloroformate, for the first time, before reacting with sodium alginate. Further, lactoferrin was conjugated on SACDs to provide lactoferrin-SACDs (Lf-SACD), which was established by immune electron microscopy (IEM) and self-assembled into brain-targeting nanomicelles. These nanomicelles were negatively charged and spherical in nature, with an average size of <200 nm. The YC1 drug loading was increased due to the cholesteryl inner cores of the nanomicelles, and the higher the grafting ratio was, the lower the critical micelle concentration (CMC) value of SACD, and the higher drug loading. The in vitro drug release, studied by bulk-equilibrium dialysis in 20 mL of 6% hydroxypropyl-β-cyclodextrin solution at 37°C, indicated a prolonged release profile. The YC1 concentration in mouse brain delivered by lactoferrin-modified nanomicelles was higher than in those delivered by non-modified nanomicelles and YC1 solution. The unique brain-targeting nanomicelle system may provide a promising carrier to deliver hydrophobic drugs across the blood-brain barrier for the treatment of brain diseases.

Citing Articles

Neuro-nanotechnology: diagnostic and therapeutic nano-based strategies in applied neuroscience.

Shabani L, Abbasi M, Azarnew Z, Amani A, Vaez A Biomed Eng Online. 2023; 22(1):1.

PMID: 36593487 PMC: 9809121. DOI: 10.1186/s12938-022-01062-y.

Functional block copolymer micelles based on poly (jasmine lactone) for improving the loading efficiency of weakly basic drugs.

Ali A, Bhadane R, Asl A, Wilen C, Salo-Ahen O, Rosenholm J RSC Adv. 2022; 12(41):26763-26775.

PMID: 36320859 PMC: 9490767. DOI: 10.1039/d2ra03962a.

A Historical Review of Brain Drug Delivery.

Pardridge W Pharmaceutics. 2022; 14(6).

PMID: 35745855 PMC: 9229021. DOI: 10.3390/pharmaceutics14061283.

Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges.

Zhang W, Mehta A, Tong Z, Esser L, Voelcker N Adv Sci (Weinh). 2021; 8(10):2003937.

PMID: 34026447 PMC: 8132167. DOI: 10.1002/advs.202003937.

Wheat Germ Agglutinin-Conjugated Disulfide Cross-Linked Alginate Nanoparticles as a Docetaxel Carrier for Colon Cancer Therapy.

Chiu H, Lim V Int J Nanomedicine. 2021; 16:2995-3020.

PMID: 33911862 PMC: 8075318. DOI: 10.2147/IJN.S302238.

References

Veiseh O, Gunn J, Zhang M . Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2009; 62(3):284-304. PMC: 2827645. DOI: 10.1016/j.addr.2009.11.002. View

Robitzer M, David L, Rochas C, di Renzo F, Quignard F . Nanostructure of calcium alginate aerogels obtained from multistep solvent exchange route. Langmuir. 2008; 24(21):12547-52. DOI: 10.1021/la802103t. View

Talukder M, Takeuchi T, Harada E . Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. J Vet Med Sci. 2003; 65(9):957-64. DOI: 10.1292/jvms.65.957. View

Liu L, Guo K, Lu J, Venkatraman S, Luo D, Ng K . Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2007; 29(10):1509-17. DOI: 10.1016/j.biomaterials.2007.11.014. View

Chen Y, Liu L . Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2011; 64(7):640-65. DOI: 10.1016/j.addr.2011.11.010. View

Liu J, Xiao Y, Allen C . Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci. 2003; 93(1):132-43. DOI: 10.1002/jps.10533. View

Wang J, Sun X, Zhang Z . Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm. 2002; 54(3):285-90. DOI: 10.1016/s0939-6411(02)00083-8. View

Wang J, del Rosario L, Demirdirek B, Bae A, Uhrich K . Comparison of PEG chain length and density on amphiphilic macromolecular nanocarriers: self-assembled and unimolecular micelles. Acta Biomater. 2008; 5(3):883-92. DOI: 10.1016/j.actbio.2008.10.019. View

Visser C, Voorwinden L, Crommelin D, Danhof M, de Boer A . Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res. 2004; 21(5):761-9. DOI: 10.1023/b:pham.0000026425.69874.8e. View

10.

Goddard E, Turro N, Kuo P, Ananthapadmanabhan K . Fluorescence probes for critical micelle concentration determination. Langmuir. 2011; 1(3):352-5. DOI: 10.1021/la00063a015. View

11.

Baker E, Baker H, Kidd R . Lactoferrin and transferrin: functional variations on a common structural framework. Biochem Cell Biol. 2002; 80(1):27-34. DOI: 10.1139/o01-153. View

12.

Pardridge W . Crossing the blood-brain barrier: are we getting it right?. Drug Discov Today. 2001; 6(1):1-2. DOI: 10.1016/s1359-6446(00)01583-x. View

13.

Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q . Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2008; 134(1):55-61. DOI: 10.1016/j.jconrel.2008.10.016. View

14.

Memisoglu E, Bochot A, Sen M, Duchene D, Hincal A . Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic beta-cyclodextrins. Int J Pharm. 2003; 251(1-2):143-53. DOI: 10.1016/s0378-5173(02)00593-8. View

15.

Cipolla M, Crete R, Vitullo L, Rix R . Transcellular transport as a mechanism of blood-brain barrier disruption during stroke. Front Biosci. 2004; 9:777-85. DOI: 10.2741/1282. View

16.

Beduneau A, Saulnier P, Benoit J . Active targeting of brain tumors using nanocarriers. Biomaterials. 2007; 28(33):4947-67. DOI: 10.1016/j.biomaterials.2007.06.011. View

17.

Letchford K, Burt H . A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007; 65(3):259-69. DOI: 10.1016/j.ejpb.2006.11.009. View

18.

Patel M, Goyal B, Bhadada S, Bhatt J, Amin A . Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2008; 23(1):35-58. DOI: 10.2165/0023210-200923010-00003. View

19.

Sethuraman V, Bae Y . TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release. 2007; 118(2):216-24. PMC: 1963443. DOI: 10.1016/j.jconrel.2006.12.008. View

20.

Terent A, Hallgren R, Venge P, Bergstrom K . Lactoferrin, lysozyme, and beta 2-microglobulin in cerebrospinal fluid. Elevated levels in patients with acute cerebrovascular lesions as indices of inflammation. Stroke. 1981; 12(1):40-6. DOI: 10.1161/01.str.12.1.40. View